BioSpace News Archive

Teva Pharmaceutical Industries Ltd. released a new report highlighting the billions of dollars saved by the healthcare system due to its generic medicines, and the Company’s contribution to economies in 2020.

BrainsWay Ltd., a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, announced that it will report its second quarter 2021 financial results as well as operational highlights before the open of the U.S. financial markets on Wednesday, August 11, 2021.

SalioGen Therapeutics, a privately held biotechnology company developing durable and broadly applicable genetic medicines through Gene Coding, today announced that the Company has strengthened its management team with multiple leadership appointments of renowned experts in their respective fields.

G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, will host a webcast and conference call to provide a corporate and financial update for the second quarter of 2021 on Wednesday, August 4, 2021 at 4:30 p.m. ET.

Novan, Inc. (“the Company” or “Novan”) (Nasdaq: NOVN), today announced the last patient has completed their planned Week-24 follow-up visit in the B-SIMPLE4 pivotal Phase 3 clinical study of SB206, a topical gel with antiviral properties for the treatment of molluscum contagiosum (“molluscum”).

PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing novel cancer therapies based on the Company’s proprietary Versamune® T-cell activating technology, announced today that its management team will present at several investor conferences listed below during the third quarter of 2021.

Acutus Medical, Inc. (“Acutus”) (Nasdaq: AFIB), an arrhythmia management company focused on improving the way cardiac arrhythmias are diagnosed and treated, will offer a variety of unique clinical and educational opportunities at the 2021 Heart Rhythm Society (HRS) conference happening July 28-31 in Boston, MA.

Evofem Biosciences, Inc., (NASDAQ: EVFM) will hold a webcast and conference call to discuss financial results and business highlights for the second quarter ended June 30, 2021 on Wednesday, August 11, 2021 at 4:30 p.m. ET (1:30 p.m. PT).

The University of Texas MD Anderson Cancer Center and Blueprint Medicines Corporation (NASDAQ: BPMC) today announced a three-year strategic research collaboration focused on accelerating development of BLU-222, an investigational precision therapy designed to target cyclin-dependent kinase 2 (CDK2).

BIOREM Inc. (TSXV: BRM) (“Biorem” or “the Company”) today announced its results for the three and six-month periods ended June 30, 2021.